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based disulphide bridge mimetic stimulate kallikrein-
related peptidase 3 activity†
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Pseudopeptides based on the kallikrein-related peptidase 3 (KLK3) activating bicyclic peptide “C-4”
comprising hydrocarbon-based disulphide bridge mimetics have been synthesized. After investigating
different synthetic approaches, the pseudopeptides were successfully cyclized from two L-allylglycine
side chains via an alkene ring-closing metathesis reaction during the peptide synthesis. The alkene-linker
was formed in a 1 : 1 E/Z isomer ratio. The resulting pseudopeptides were almost as potent as the
parent peptide, increasing the activity of KLK3 over four-fold at 200 mgml1 (130–140 mM) concentrations.Introduction
The human kallikrein-related peptidases, a family of 15 closely
related serine proteases (KLK1–KLK15), are attracting increased
attention due to their role as biomarkers for screening, diagnosis,
and monitoring of various cancers.1 Among these KLK3, also
known as prostate-specic antigen (PSA), is the most studied. It
has been shown to be highly prostate specic and there is
growing evidence supporting its use for targeted treatment and
selective imaging of prostate cancer.2,3 In prostate cancer, the
KLK3 expression is reduced and more aggressive tumours have
lower KLK3 levels than less aggressive ones.4–6 At the same time
the levels of KLK3 in blood are elevated due to increased leakage
from the prostate, however, in blood circulation the majority of
KLK3 is rapidly inactivated by endogenous protease inhibitors.7
KLK3 exerts an antiangiogenetic activity that is related to its
enzymatic activity.8–10 It has therefore been suggested that
tumour angiogenesis and thus prostate cancer growth might be
controlled by increasing the proteolytic activity of KLK3.9,11
Peptide 1 (C-4), developed by Stenman and coworkers, is so
far the most potent KLK3 activating compound,12 increasing the
proteolytic activity of KLK3 several-fold at micromolar concen-
trations (Table 3). Interestingly, all known potent compoundsulty of Pharmacy, University of Helsinki,
inki.
ences, University of Eastern Finland and
sity of Helsinki and Helsinki University
istry and Molecular Biology, University of
tion (ESI) available. See DOI:
Chemistry 2013having this unique biological activity are peptides.11 Peptide 1 is
likely to bind near the active site of KLK3, as the binding could
be inhibited by monoclonal antibodies binding close to the
active site.12 Recent studies demonstrate that peptide 1
enhances the antiangiogenic activity of KLK3 in an endothelial
cell tube formation assay.13
Peptide 1 consists of 13 amino acids and is cyclized by two
disulphide bridges, one between Cys-1 and Cys-13, and one
between Cys-5 and Cys-10. The side chains of Tyr-4, Ile-6 and
Trp-11 have previously been identied to be important for their
biological activity.14 As these amino acid residues are directly
attached to the central disulphide bridge, this part of the
peptide was considered to be most important for the develop-
ment of pseudopeptides of 1. In vivo stable replacements of the
central disulphide bridge would result in pseudopeptides with
new molecular backbones.
We have earlier reported the successful synthesis of a series
of orthogonally protected disulphide bridge mimetics (2a–d),15
and in the present study our aim was to synthesize pseudo-
peptides of peptide 1 with these mimetics as replacements for
the centrally positioned disulphide bridge. As described earlier,
2a–d can easily be converted to 3a–d, which have a more suit-
able combination of protecting groups for solid phase peptide
synthesis using Fmoc-chemistry.
An additional objective was to identify all important side
chains in 1 using multiple alanine replacements. In our earlier
single alanine replacement study the importance of other
amino acid side chains except Tyr-4, Ile-6 and Trp-11 was not
fully determined.14 As the pseudopeptides are cyclized in a way
that gives them a new backbone, we wanted to clarify if some
parts of the original peptide structure could be simplied













































View Article OnlineResults and discussion
Identication of all important amino acid side chains in
peptide 1
We started the current study by performing simultaneous
substitutions of more than one amino acid residue with alanine
on peptide 1. The peptides were synthesized on a peptide
synthesizer using Fmoc-chemistry on Rink AM resin, resulting
in peptides with a C-terminal amide instead of the C-terminal
carboxylic acid. This difference has however no signicant
inuence on the biological activity (unpublished data). The
effect of the peptides on the proteolytic activity of KLK3 was
tested in vitro using a chromogenic peptide substrate according
to a published procedure (Table 1).16
Although the original single alanine replacement study
indicated that residues Glu-7, His-8 and His-9 could all be
replaced with alanines, His-9 was found to be necessary for
retaining full activity when two or three of these residues were
replaced with alanines at the same time (peptides 4–7).Table 1 Synthesized analogues of peptide 1, and their effects at 20 mgml1 (13–
15 mM) concentration on the proteolytic activity of KLK3, the amino acid














550 | Med. Chem. Commun., 2013, 4, 549–553Furthermore, replacing Cys-5 and Cys-10 with alanines in
combination with replacing Ile-6 and His-9 with cysteines to
form the centrally positioned disulphide bridge resulted in an
inactive peptide (peptide 8). Interestingly, Val-2 and Thr-12
could not be replaced simultaneously with alanines (peptide 9).
Thus, the amino acids directly connected to the cysteine resi-
dues of both disulphide bridges seem to have a signicant
inuence on the biological activity of 1.
The identied important side chains can either have direct
interactions with the binding site on KLK3 or have a critical
inuence on the biologically active conformation of the peptide.
According to a recent report, the binding site of 1 was suggested
to be located in the kallikrein loop region on KLK3,17 which
makes the analysis of the binding site more challenging due to
the exibility of the loop region.
Ile-6 was also replaced with different non-polar amino acids
(peptides 10–13). Interestingly, this residue could be replaced
with phenylalanine and leucine, which both have lipophilic side
chains of similar size to that of isoleucine. However, consider-
ably smaller amino acids such as glycine or alanine were not
successful replacements.Synthesis and evaluation of the pseudopeptides
The pseudopeptides were designed based on our previously
reported disulphide bridge mimetics 2a–d/3a–d.15 The three
most potent peptides, original peptide 1 and analogues 5 and
10, were used as starting peptides in this part of the study.
Peptide 5 was of primary interest due to its lower molecular
weight. The pseudopeptides were synthesized manually using
Fmoc-chemistry on Cys(Acm)-preloaded Wang resin.
Our initial strategy was to use the orthogonally protected
disulphide bridge mimetics 3a–d directly in solid phase peptide
synthesis. However, an initial study with Fmoc-chemistry on
Wang resinwithmimetic3b faileddue toproblems in the selective
removal of themethyl ester and/or phthalimide protecting groups
from the resin-bound intermediate 14 during peptide synthesis.
We also synthesized the small ring 18 with the intention of
using it as an Fmoc-protected building block in solid phase
peptide synthesis aer hydrolysis of the methyl ester. Linear
tetrapeptide 15 was straightforwardly accessed in solution
starting from Boc-Ile, coupling each residue as an amino acid
methyl ester and subsequently hydrolyzing the ester. The Boc
and the tert-butyl ester groups of 2b were removed with TFA
before coupling, resulting in 16. The risk for racemization in theThis journal is ª The Royal Society of Chemistry 2013
Scheme 1 (a) EDC$HCl, HOBt, DIPEA/MeCN, 0 C; (b) 1.75 M HCl/EtOAc; (c)













































View Article Onlinecoupling steps was suppressed by using EDC$HCl with HOBt
and DIPEA as coupling reagents. Aer selectively removing the
Boc-group from 17 with 1.75 M HCl in EtOAc at room tempera-
ture for 1 h followed by cyclization with TBTU, HOBt and DIPEA,
18 was obtained in good yield (42% over two steps). Although
methyl ester groups can generally be selectively removed in the
presence of Fmoc groups using Me3SnOH in 1,2-dichloroethane
(DCE), all our attempts to perform this reaction on 18 failed. This
might be due to the steric hindrance around the ester group,
from the neighbouring Trt- and Fmoc-groups (Scheme 1).
Aer the pioneering work by Miller and Grubbs,18 ring-
closing alkene metathesis reactions on peptides have been
successfully reported for a wide variety of peptides.19 This
inspired us to attempt this synthetic strategy also for our
pseudopeptides. However, the drawbacks with this strategy are
that only the alkene-based mimetics can be accessed and that
the E/Z ratio of the formed alkenes cannot be controlled.
Peptide 19 was rst synthesized using Fmoc-chemistry onWang
resin with L-allylglycine residues as replacements for theTable 2 Ring-closing alkene metathesis reaction optimization
Starting material Catalysta Additiveb Solventc
19 HG2 TFE : DCM 4
20a HG2 TFE : DCM 4
20b HG2 DCM




20b HG2 LiCl/DMF DCE
20b G2 LiCl/DMF DCE
21 HG2 DCE
21 HG2 LiCl/DMF DCE
22 HG2 LiCl/DMF DCE
23 HG2 LiCl/DMF DCE
a HG2, Hoveyda–Grubbs 2nd generation catalyst; G2, Grubbs 2nd generation
dichloromethane; DCE, 1,2-dichloroethane. d r.t., room temperature; MW,
product was the main component and the main other component was a t
This journal is ª The Royal Society of Chemistry 2013cysteines in positions 5 and 10. The ring-closing alkene
metathesis reaction was rst attempted for cleaved 19 and
resin-bound 20a and 20b, but all attempts were unsuccessful as
the MS spectra did not reveal even trace amounts of the cyclized
peptide independent of the conditions used (Table 2). Thus, as
unreacted starting material was the main component in all
unsuccessful reactions, the full length peptide was unreactive in
the ring-closing metathesis reaction.We rened our strategy by stopping the peptide synthesis
aer attachment of the second Fmoc-L-allylglycine, resulting in
intermediate 21. An initial attempt to perform the ring-closing
metathesis on 21 using the Hoveyda–Grubbs 2nd generation
catalyst (HG2) in DCE at room temperature for 48 h was
unsuccessful, but in later attempts the reaction was found to be
highly successful when using LiCl in DMF as an additive and
performing the reaction under microwave heating at 100 C for
60 min (Table 2). The only impurity was a trace amount of
uncyclized starting material. Intermediates 22 and 23 were also
cyclized successfully using the samemethodology. The addition
of LiCl in DMF in combination with microwave heating to
enable/improve cyclization of peptides with two L-allylglycine
residues on Wang resin by ring-closing metathesis reaction has
also been presented previously by other groups.20 Pre-treatmentTemperatured [C] Time [h] Producte
: 1 r.t. 24 Not detected
: 1 r.t. 48 Not detected
r.t. 24 Not detected
: 1 60 1 Not detected
60 1 Not detected
60 20 Not detected
60 20 Not detected
100 (MW) 1 Not detected
100 (MW) 1 Not detected
r.t. 48 Not detected
100 (MW) 1 High conversion
100 (MW) 1 High conversion
100 (MW) 1 High conversion
catalyst. b DMF,N,N-dimethylformamide. c TFE, triuoroethanol; DCM,
microwave heating. e Analyzed by MS, in the case of high conversion the
race amount of the starting material.
Med. Chem. Commun., 2013, 4, 549–553 | 551
Scheme 2 (a) HG2, 0.4 M LiCl in DMF (10% (v/v))/DCE, 100 C, MW; (b) (i) solid-
phase peptide synthesis (coupling of Tyr(tBu), Ala, Val and Cys(Acm)), (ii) reagent K
(cleavage from resin); (c) I2, HCl/AcOH, H2O.
Table 3 Effect on the proteolytic activity of KLK3 by peptide 1 and the
synthesized pseudopeptides 24–26 at 20 mg ml1 concentrationa (the activity of
KLK3 alone is 100%)
Pseudopeptide
KLK3 proteolytic
activity [%] (mean  SE, n ¼ 4)
1 625  36
24 225  15
25 189  9
26 223  15
a Corresponding to 13 mM for 1, 25 and 26, and 14 mM for 24.
Fig. 1 Effect on the proteolytic activity of KLK3 by peptide 1 and the synthesized













































View Article Onlinewith LiCl in DMF has also been reported to enable a similar
cyclization of peptides with thermal heating (Scheme 2).21
There are several reported NMR spectroscopy methods for
studying the E/Z ratio of the formed alkene.22,23 Product 27 (the
cleaved ring-closing alkene metathesis product of 22) was
studied by NMR spectroscopy according to the method reported
by Bhattacharya et al.22 The sample was puried by preparative
HPLC. The NMR spectra from the crude and puried ring-
closing alkenemetathesis product showed that the E/Z ratio was
approximately 1 : 1.
As the only impurity was a trace amount of uncyclized
starting material in all three cyclizations, peptide synthesis was
continued on a solid support with addition of the remaining
four amino acids (Tyr-4, Ala-3, Val-2 and Cys-1). The pseudo-
peptides were cleaved from the resin, and the Acm-protected
cysteines were then deprotected and cyclized with iodine in
acetic acid in the presence of aqueous HCl. The yield of the
crude pseudopeptides 24, 25 and 26 were 37%, 65% and 81%,
respectively. Aer purication by preparative HPLC to over 90%
purity, the total yield for 24, 25 and 26went down to 1%, 3% and
6%, respectively. To conrm that the purication procedure
had not changed the E/Z isomer ratio, the NMR spectra of the
puried pseudopeptide 26 showed that the E/Z isomer ratio was
unchanged. In biological testing, the pseudopeptides 24, 25 and
26 increased the activity of KLK3 to 225%, 189% and 223%,
respectively, of that of KLK3 alone at a concentration 20 mg ml1
(Table 3). The original peptide 1 increased the activity to 625%552 | Med. Chem. Commun., 2013, 4, 549–553at the same concentration. Increasing the concentration of
pseudopeptides 24, 25 and 26 showed that the stimulating
effect approached the level of peptide 1 at higher concentrations
(Fig. 1). At 200 mg ml1 concentration they stimulated the KLK3
activity about four-fold.
In order to test if pseudopeptides with approximately half
the size of the original peptide can increase the activity of KLK3,
we synthesized pseudopeptides 28a, 28b and 29. Pseudopep-
tides 28a and 28b were synthesized according to the previously
described procedure with the exception that 28a was synthe-
sized on Trp(Boc)-preloadedWang resin and 28b on Rink amide
resin. Pseudopeptide 29 has 8-aminooctanoic acid as a
replacement of the disulphide bridge and the small ring, and
this linker was introduced in the peptide synthesis as an Fmoc-
protected amino acid. The yield of the crude pseudopeptides













































View Article Onlinepurication by preparative HPLC to over 90% purity, the total
yield for 28a, 28b and 29 went down to 7%, 3% and 3%,
respectively. None of these smaller pseudopeptides increased
the activity of KLK3 at a concentration of 20 mg ml1 (data not
shown), which clearly indicates that neither ring alone is bio-
logically active.Conclusions
Based on the multiple alanine replacement study, we succeeded
in identifying the important amino acid side chains in peptide
1. The only non-important side chains were Glu-7 and His-8, as
these could simultaneously be replaced with alanines. The
multiple alanine replacement showed that most amino acid
side chains are important and the size of the peptide will
therefore be difficult to reduce. Furthermore, Ile-6 could be
replaced with leucine and phenylalanine, which are similar in
size and non-polar character.
We have developed a general synthetic route towards the
pseudopeptides with a centrally positioned alkene-based
disulphide bridge mimetic. However, the alkene was formed as
a 1 : 1 mixture of the E and Z isomers, and the two isomers
could not be separated. The same amino acid replacements that
were allowed for peptide 1 were also allowed for the pseudo-
peptides. The most potent pseudopeptides (24 and 26)
increased the activity of KLK3 to over 200% (doubling the
activity) at a concentration of 20 mg ml1 (13–14 mM) and they
were almost as potent as the parent peptide at higher concen-
trations, increasing the activity of KLK3 over four-fold at a
concentration of 200 mg ml1 (130–140 mM). As the pseudo-
peptides have a new backbone consisting of the alkene-linker,
we also synthesized pseudopeptides corresponding to either the
small or the large ring on peptide 1. These smaller pseudo-
peptides did not stimulate the KLK3 activity which indicates
that it will be difficult to drastically decrease the size of the
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